|
|
|
|
|
Dear <<First Name>>,
Time is running out to take advantage of our 3D Complete™ Human Liver Microtissue Kits at a 30% discount, and be eligible for our "Try now. Travel later." offer. We'll help send you to a conference to present your data!
Additionally, there's always a chance to meet InSphero in person. Visit one of our 3 posters at FutureTox III in the USA or in early December at our joint European workshop in Vienna.
|
|
|
3D Complete™Human Liver Microtissue Kits
A convenient kit for evaluating 3D InSight™ Human Liver Microtissues
InSphero’s 3D InSight™ Human Liver Microtissues are being integrated into the in vitro safety and efficacy workflows in the world's leading pharmaceutical and chemical companies.
The 3D Complete™ Kit is a simple way to help you make the same decision, including the essentials needed to get started:
Order before December 31, 2015 and receive a 30% discount.
|
|
|
|
Seize December!
In a recent screen of 30 known DILI-inducing compounds, nearly 70% exhibited lower IC50 values following repeat-dosing in 3D primary hepatocytes over 14 days compared to standard 2D hepatocyte assays using the same cells. Experience the enhanced sensitivity and superior biological relevance provided by InSphero's 3D InSight™ Human Liver Microtissues.
Submit your compounds today for the final 14 Day Hepatotoxicity Testing Service run of 2015, initiating on Tuesday, December 1. Just $990 per compound!
|
|
Transforming 21st Century Science into Risk Assessment and Regulatory Decision-Making
Meet InSphero at FutureTox III
Date: November 11 - 20, 2015
Find out more about FutureTox III
|
|
|
Promega, InSphero & BD Bioscience Seminar: Reliable Methods & Tools to Study Cellular Responses
Promega, InSphero & BD Biosciences will give scientists the opportunity to learn about various methods and tools to study different aspects of cellular biology.
Location: ARCHOTEL Wimberger, Neubaugürtel 34-36, 1070 Vienna, Austria
Date and Time: Wednesday, 02 December 2015, 10:30 - 15:00
Find out more about the seminar
|
|
|
|
|
|
|
|
|
|
|
